Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France

NCT06092879 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

201

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myeloid Leukemia

Interventions

OTHER: Asciminib

Sponsor

Novartis Pharmaceuticals